Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
Medical Devices
Intellectual Property
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.


Designer Diagnostics Medical DevicesDesigner Diagnostics (website) is a wholly-owned medical devices subsidiary of Nutra Pharma Corporation. The Company was established in 2005 for the marketing and sales of rapid diagnostics test kits for infectious diseases, including Tuberculosis and NonTuberculous Mycobacteria (NTM).

Designer Diagnostics Test Kits provide a highly cost effective, highly efficient, low infrastructure solution for identifying and testing sensitivity of Nontuberculous Mycobacteria (NTM) that are capable of utilizing paraffin wax as a sole carbon source or those that are hydrophobic. Additionally Designer Diagnostics provides an efficient solution for the rapid identification and sensitivity testing of Tuberculosis (TB).

Benefits of the Designer Diagnostics' Test Kits:

  • Ability to provide much earlier diagnosis. (less than 1 week)
  • Long shelf life
  • Can be stored in extremely hostile environments
  • Cost effective compared to all other traditional methods
  • Does not require new large capital expenditures
  • Can be easily integrated into any lab environment from the most advanced to a simple mobile lab
  • Results can be quickly translated into PCR testing and other antibiotic sensitivity testing techniques
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.


Recent News
October 27, 2015 Publishes New SNNLive Video Interview With Nutra Pharma Corporation

October 22, 2015
Nutra Pharma's Rik Deitsch Interviewed by The Life Sciences Report

September 09, 2015
Nutra Pharma To Present at Upcoming Investment Conference

Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
Facebook   Twitter
Privacy Policy Code of Ethics